FDA approves AbbVie Venclexta and acalabrutinib combo for previously untreated CLL patients
Reuters
Feb 20
FDA approves AbbVie Venclexta and acalabrutinib combo for previously untreated CLL patients
AbbVie Inc. said the U.S. Food and Drug Administration approved a supplemental new drug application for the all-oral, fixed-duration combination of VENCLEXTA (venetoclax) and acalabrutinib to treat previously untreated adult patients with chronic lymphocytic leukemia. The approval was supported by data from the Phase 3 AMPLIFY trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602200200PR_NEWS_USPR_____CG92191) on February 20, 2026, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.